SMARCA4 and neoplasm: As expected, we also detected lower protein levels of EGFR and TNS4 in tumor tissues of SMARCA4-R1157W mutant CDX models after treatment with GSK-PTi and BBAi-1 by western blot (Fig. 6f) and IHC analysis (Fig. 6g) than those in SMARCA4-WT CDX models.